PDF(Pubmed)
Abstract：
UNASSIGNED: We compared radical prostatectomy (RP) and radiotherapy (RT) as local therapies for primary tumors and examined their associations with survival outcomes and urinary tract complications in patients with oligometastatic prostate cancer (omPC).
UNASSIGNED: We evaluated the data of 85 patients diagnosed with omPC who underwent local therapy for primary tumors between January 2008 and December 2018. Of the 85 patients, 31 underwent prostate RT, while 54 underwent RP. Oligometastatic disease was defined as the presence of fewer than five metastatic lesions without visceral metastasis. Urinary tract complications, progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) were evaluated using the Kaplan-Meier method and Cox regression analyses.
UNASSIGNED: Patients treated with RT showed higher prostate-specific antigen levels. There was no significant difference in the 5-year PFS (52.5% vs. 37.9%, p=0.351), CSS (67.6% vs. 84.7%, p=0.473), or OS (63.6% vs. 73.8%, p=0.897) between the RT and RP groups. In the multivariate analyses, the type of local therapy was not associated with PFS (hazard ratio [HR]=1.334, p=0.356), CSS (HR=0.744, p=0.475), or OS (HR=0.953, p=0.897).
UNASSIGNED: Therefore, RP seems to be a possible treatment option for patients with omPC, exhibiting oncologic outcomes comparable to those with RT.
UNASSIGNED: We evaluated the data of 85 patients diagnosed with omPC who underwent local therapy for primary tumors between January 2008 and December 2018. Of the 85 patients, 31 underwent prostate RT, while 54 underwent RP. Oligometastatic disease was defined as the presence of fewer than five metastatic lesions without visceral metastasis. Urinary tract complications, progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) were evaluated using the Kaplan-Meier method and Cox regression analyses.
UNASSIGNED: Patients treated with RT showed higher prostate-specific antigen levels. There was no significant difference in the 5-year PFS (52.5% vs. 37.9%, p=0.351), CSS (67.6% vs. 84.7%, p=0.473), or OS (63.6% vs. 73.8%, p=0.897) between the RT and RP groups. In the multivariate analyses, the type of local therapy was not associated with PFS (hazard ratio [HR]=1.334, p=0.356), CSS (HR=0.744, p=0.475), or OS (HR=0.953, p=0.897).
UNASSIGNED: Therefore, RP seems to be a possible treatment option for patients with omPC, exhibiting oncologic outcomes comparable to those with RT.
摘要：
■我们比较了根治性前列腺切除术（RP）和放疗（RT）作为原发性肿瘤的局部治疗，并检查了它们与寡转移性前列腺癌（omPC）患者的生存结局和尿路并发症的关系。
我们评估了2008年1月至2018年12月期间接受原发性肿瘤局部治疗的85例确诊为omPC患者的数据。85名患者中,31例行前列腺RT，而54人接受了RP。轻度转移疾病被定义为存在少于五个无内脏转移的转移性病变。尿路并发症,无进展生存期（PFS），癌症特异性生存率（CSS），使用Kaplan-Meier方法和Cox回归分析评估总生存期(OS).
■接受RT治疗的患者显示出更高的前列腺特异性抗原水平。5年PFS没有显着差异（52.5%与37.9%,p=0.351),CSS（67.6%与84.7%,p=0.473),或操作系统（63.6%与73.8%,RT和RP组之间的p=0.897）。在多变量分析中，局部治疗的类型与PFS无关（风险比[HR]=1.334，p=0.356），CSS（HR=0.744，p=0.475），或OS（HR=0.953，p=0.897）。
■因此，RP似乎是omPC患者的一种可能的治疗选择，表现出与RT相当的肿瘤学结果。
我们评估了2008年1月至2018年12月期间接受原发性肿瘤局部治疗的85例确诊为omPC患者的数据。85名患者中,31例行前列腺RT，而54人接受了RP。轻度转移疾病被定义为存在少于五个无内脏转移的转移性病变。尿路并发症,无进展生存期（PFS），癌症特异性生存率（CSS），使用Kaplan-Meier方法和Cox回归分析评估总生存期(OS).
■接受RT治疗的患者显示出更高的前列腺特异性抗原水平。5年PFS没有显着差异（52.5%与37.9%,p=0.351),CSS（67.6%与84.7%,p=0.473),或操作系统（63.6%与73.8%,RT和RP组之间的p=0.897）。在多变量分析中，局部治疗的类型与PFS无关（风险比[HR]=1.334，p=0.356），CSS（HR=0.744，p=0.475），或OS（HR=0.953，p=0.897）。
■因此，RP似乎是omPC患者的一种可能的治疗选择，表现出与RT相当的肿瘤学结果。
